Syschem (India) Ltd

Syschem (India) Ltd has witnessed a notable shift in its valuation parameters, moving from an expensive to a very expensive rating, driven primarily by its elevated price-to-earnings (P/E) and price-to-book value (P/BV) ratios. This change reflects evolving market perceptions and invites a closer examination of the company’s price attractiveness relative to its historical averages and peer group within the Pharmaceuticals & Biotechnology sector.

Syschem (India) Ltd., a micro-cap pharmaceutical API manufacturer, delivered a remarkable turnaround in Q3 FY26 with net profit surging to ₹4.17 crores—a sequential jump of 119.47% from Q2's ₹1.90 crores and an impressive 734% year-on-year leap from ₹0.50 crores in Q3 FY25. The company's stock responded enthusiastically, rallying 7.00% on February 02, 2026 to close at ₹51.99, though the shares remain 16.15% below their 52-week high of ₹62.00.

Syschem (India) Ltd has seen its investment rating upgraded from Hold to Buy, reflecting a marked improvement across key parameters including quality, valuation, financial trends, and technical indicators. This upgrade, effective from 1 February 2026, follows a period of robust financial performance and evolving market sentiment that positions the company favourably within the Pharmaceuticals & Biotechnology sector.

Syschem (India) Ltd’s investment rating has been downgraded from Buy to Hold as of 27 Jan 2026, reflecting a nuanced reassessment of its technical indicators, valuation metrics, financial trends, and overall quality. Despite impressive recent financial performance, the stock’s technical outlook and valuation premium have prompted a more cautious stance among analysts.

Syschem (India) Ltd is rated 'Buy' by MarketsMOJO, with this rating last updated on 20 January 2026. However, the analysis and financial metrics discussed here reflect the stock's current position as of 25 January 2026, providing investors with the latest insights into the company’s performance and outlook.

Syschem (India) Ltd is rated 'Buy' by MarketsMOJO, with this rating last updated on 07 Jan 2026. However, the analysis and financial metrics discussed here reflect the company’s current position as of 12 January 2026, providing investors with the latest insights into its performance and outlook.

Syschem (India) Ltd, a player in the Pharmaceuticals & Biotechnology sector, has seen its investment rating downgraded from Buy to Hold as of 30 Dec 2025. This adjustment reflects a nuanced reassessment across four key parameters: quality, valuation, financial trend, and technicals. Despite robust financial performance, the stock’s technical indicators and valuation metrics have prompted a more cautious stance from analysts.

Syschem (India) Ltd is rated Buy by MarketsMOJO, with this rating last updated on 09 Dec 2025. However, the analysis and financial metrics presented here reflect the stock’s current position as of 24 December 2025, providing investors with the latest insights into its performance and outlook.

Syschem (India), a microcap player in the Pharmaceuticals & Biotechnology sector, has experienced a revision in its market evaluation reflecting a nuanced view of its recent financial and technical performance. This adjustment comes amid a backdrop of strong operating profit growth contrasted with valuation concerns and moderate management efficiency.

Syschem (India) Ltd., a micro-cap pharmaceutical API and intermediates manufacturer, reported net profit of ₹1.67 crores for Q1 FY26 (Apr-Jun'25), marking a dramatic turnaround from ₹0.14 crores in the year-ago quarter—a staggering 1,092.86% year-on-year surge. However, the sequential picture reveals fragility: profits jumped 263.04% quarter-on-quarter from ₹0.46 crores in Q4 FY25, but this follows an exceptionally weak base marked by a loss-making Q3 FY25.

Syschem (India) Ltd is experiencing notable buying activity, with a significant rise in its stock price today, contrasting with a decline in the Sensex. Over the past week, Syschem has shown strong performance, outperforming its sector and trading above key moving averages, indicating robust market positioning.

Syschem (India), a microcap in the Pharmaceuticals & Biotechnology sector, has experienced a recent evaluation adjustment. The company has shown significant growth, with net sales rising by 37.96% and net profit soaring by 1092.86%. However, it faces challenges in management efficiency, indicated by a low return on equity.

Syschem (India) Ltd is experiencing notable buying activity, with a significant rise today, reversing a two-day decline. The stock has shown strong performance over the past week and months, significantly outperforming the Sensex. Factors contributing to this trend include consistent performance above moving averages and increased interest in the microcap pharmaceutical sector.

Syschem (India), a microcap in the Pharmaceuticals & Biotechnology sector, has recently seen a shift in its technical outlook. The company reported significant growth in net sales and net profit, outperforming the broader market. However, it faces challenges with management efficiency and trades at a premium compared to peers.